Activation of the Wnt/b-catenin pathway has recently been shown to be crucial to the establishment of leukemic stem cells in chronic myeloid leukemia. We sought to determine whether b-catenin was correlated to clonogenic capacity also in the acute myeloid leukemia (AML) setting. Eighty-two patients were retrospectively evaluated for b-catenin expression by Western blot. b-Catenin was expressed (although at various protein levels) in 61% of patients, and was undetectable in the remaining cases. In our cohort, b-catenin expression was correlated with the clonogenic proliferation of AML-colony forming cells (AML-CFC or CFU-L) in methylcellulose in the presence of 5637-conditioned medium, and more strikingly with self-renewing of leukemic cells, as assessed in vitro by a replating assay. In survival analyses, b-catenin appeared as a new independent prognostic factor predicting poor event-free survival and shortened overall survival (both with Po0.05). Furthermore, variations in b-catenin protein levels were dependent on post-transcriptional mechanisms involving the Wnt/ b-catenin pathway only in leukemic cells. Indeed, b-catenin negative leukemic cells were found to increase b-catenin in response to Wnt3a agonist in contrast to normal counterparts. Altogether, our data pave the way to the evaluation of Wnt pathway inhibition as a new rationale for eradicating the clonogenic pool of AML cells.
Introduction
Wnt/b-catenin signaling is a morphogenic pathway that governs early embryo patterning and organogenesis in embryo development. Its implication in the self-renewal of normal adult stem cells raised major interest in the fields of regenerative medicine and cancer. [1] [2] [3] As b-catenin, the main effector of the canonical Wnt pathway, was linked to clonogenic growth of various malignancies, [4] [5] we asked whether it could also influence leukemic colony forming cells (CFU-L). These rare progenitors support self-renewal (in the minority) or limited differentiation (in the bulk of the disease) of acute myeloid leukemia (AML) blasts. The frequency of relapse in AML is thought to be due to the lack of eradication of the self-renewing part of AML cells, the so-called leukemic stem cells pool. In vitro assessment of different growth patterns in AML cells have emerged from some pioneer studies, 6, 7 but the ability to form colonies in methylcellulose allowed to gain more insight into the definition of true CFU-L. Later, these preliminary findings were confirmed by classifying CFU-L based on autonomous growth or dependancy upon addition of exogenous growth factors. 8 Wnt pathway controls self-renewal of hematopoietic stem cells (HSC) through regulation of b-catenin. [9] [10] [11] In HSC, b-catenin also modulates survival and growth factor response both in vitro and in vivo, while inhibiting differentiation. [11] [12] [13] [14] The importance of b-catenin in the maintenance of the HSC pool echoes in many hematological malignancies of lymphoid or myeloid origin. [15] [16] [17] [18] [19] [20] [21] As clonogenic test of AML cells at diagnosis are routinely performed in our lab for newly diagnosed patients, we tried to identify b-catenin expression in unsorted bulk cells to know whether it could correlate with enhanced clonogenic properties. We also studied the influence of Wnt stimulation in the accumulation of b-catenin in normal CD34 þ or leukemic cells and along myelomonocytic maturation induced in vitro.
We confirm that Wnt signaling is deregulated in AML as assessed by b-catenin expression (which is rapidly lost upon induction of differentiation in normal precursors), and is correlated to enhanced clonogenic proliferation of CFU-L. Moreover, b-catenin expression appears as a new prognostic factor independently correlated with relapse and shorter survival. Finally, the Wnt pathway could be regulated in AML, thus suggesting a different responsiveness to Wnt agonists of AML comparatively to normal counterparts.
Materials and methods

Primary cells and cell lines
Leukemic blasts from randomly selected 82 patients with newly diagnosed AML, were obtained upon informed consent from bone marrow aspirates by Ficoll-Hypaque density gradient centrifugation. This technique ensures high blastic cells percentages (median 92% of leukemic cells in the samples). Cells were either immediately processed or cryopreserved in Iscove's modified Dulbecco medium (IMDM) with 10% dimethylsulfoxyde and 50% fetal calf serum (FCS) for further handling. All patients received induction therapy (anthracycline days 1-5 and cytosine arabinoside continuously infused days 1-7), further consolidation therapy being given accordingly to French cooperative trials protocols, stratified by age. Normal bone marrow CD34 þ were sorted by the means of immunomagnetic separation column (Miltenyi Biotech, Germany). The purity of CD34 þ cells reached 85-98% according to flow cytometry.
Leukemic immature (KG1) and myelomonocytic (U937) cell lines were purchased from DSMZ (Germany), and grown in IMDM þ 10% FCS and RPMI þ 10% FCS, respectively, with penicillin/streptomycin at 371C and 5% CO 2 .
Differentiation of CD34 þ normal progenitors in vitro CD34 þ cells were maintained in liquid culture and differentiated in six-well plates in IMDM þ 10% FCS, supplemented with stem cell factor (SCF, 100 ng/ml), Interleukin 3 (IL-3, 10 ng/ ml), Flt3 ligand (FL, 50 ng/ml) and granulocyte macrophagecolony stimulating factor (GM-CSF, 50 ng/ml) for myelomonocytic differentiation (for 14 days) (all cytokines purchased from R&D Systems, Minneapolis, MN, USA). Input plating was 4 Â 10 5 /ml, and cells were counted and diluted with fresh medium with cytokines ( þ /À Wnt ligands) every 2 days. When indicated, cells were cultured under the same conditions with recombinant Wnt3a (20 ng/ml) or Wnt5a (0.3 mg/ml) from R&D Systems. Choice of Wnt dosage was guided by manufacturer's guidelines and by publication by Willert et al., 12 who used purified Wnt3a and demonstrated that accumulation of b-catenin is comparable between 20 and 1000 ng/ml. Expression of differentiation markers (CD34, CD38, CD33, CD11b and CD14) was assessed at day 3, 5, 7, 10 and 14 by flow cytometry. At each time point, 2 Â 10 5 cells were also lysed for further blotting.
Reverse transcriptase-polymerase chain reaction analysis
Total RNAs were extracted using Qiagen RNAeasy kit, according to manufacturer's instructions, and were reverse-transcribed using the Superscript II Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA). Of a 20 ml cDNA reaction 5 ml was used as template for amplification with the following specific primers. 
Western blotting
Cells (0.5-1 Â 10 6 ) were reduced in Laemmli sample buffer and then boiled for 10 min at 1001C. Proteins were resolved on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred to nitrocellulose membrane (Hybond-C Super, Amersham Pharmacia Biotech, Little Chafont, UK). Membranes were blocked in Tris buffer saline TBS-Tween 0.05% with 5% nonfat milk for 1 h, and then incubated with proper antibodies. We purchased monoclonal anti-b-catenin from BD Transduction Laboratories, anti-actin from Sigma (St Louis, MO, USA). All antibodies were diluted 1/1000 in TBSTween 0.05%, except anti-actin that was used 1/10 000. Membranes were blotted overnight at 41C, washed three times, and blotted with appropriate anti-mouse IgG antibody coupled to horseradish peroxydase. Detection was achieved using Pierce Supersignal chemiluminescent substrate.
Clonogenic assays
Leukemic blast primary colony assay was performed as previously described. [22] [23] Briefly, 3 Â 10 5 cells were resuspended in methyl-cellulose semi-solid medium with (PE1 þ , Plating Efficiency at 1 week) or without (PE1-) 10% human bladder carcinoma cell line 5637 conditioned medium (5637 CM). A total of 1 Â 10 5 cells was then plated in 35 mm Petri dishes in triplicate (1 ml mixture/dish), and incubated at 371C and 5% CO 2 humidified atmosphere. At day 7, the leukemic colonies (420 cells) and clusters (45 cells) were scored under an inverted microscope. As the growth of clusters or colonies depends on intrinsic blastic characters, clusters and colonies were referred as CFU-L. Cells were washed, counted and re-seeded at 1 Â 10 5 /ml in the same solid medium with 5637 CM for assessment of replating capacity (plating efficiency at 2 weeks (PE2)) at day 15.
Statistical analysis
Influence of b-catenin expression was evaluated on patients clinical and biological characteristics using the w 2 test and Fisher's exact test for categorical variables. Survival curves were plotted using the product-limit method of Kaplan-Meier and compared with the log-rank test. Mann-Whitney test was carried out for comparison of medians from nonparametric data. Cox regression model was used for the identification of prognostic factors, those linked with RFS and OS with Po0.1 in univariate analysis were subsequently assessed in multivariate analysis (level for significance: Po0.05) 
Results
Expression
Correlations between b-catenin expression and usual clinico-biologic features in patients
Main characteristics of the population are summarized in Table 1 . b-catenin expression was not found to be correlated with CD34 expression in 53 patients (median CD34 þ cells
However, in immature M0-M2 subtypes (usually CD34 þ ), median CD34 expression was 10% (n ¼ 13) versus 90% (n ¼ 13) in b-catenin À and b-catenin þ , respectively (P ¼ 0.024). This correlation was lost in M4-M5 leukemias (usually CD34 low), since median CD34 expression was 23 and 29.5%, respectively (P ¼ 0.86). As b-catenin was also preferentially expressed in monocytic rather than immature leukemias (M4-M5 versus M0-M2, P ¼ 0.02, 
Clinical outcome is influenced by b-catenin expression in AML blasts
b-Catenin expression did not influence CR (data not shown). Expression of b-catenin is associated with both shortened relapse-free survival (RFS, log-rank P ¼ 0.012, n ¼ 49) and overall survival (OS, log-rank Po0.01, n ¼ 82) (Figure 2 ). In Table 1 Initial clinical characteristics of 82 patients with acute myeloid leukemia according to b-catenin expression levels 
Regulation of b-catenin levels in leukemic myeloid cells differs from normal cells
In normal CD34 þ progenitors b-catenin is strongly expressed but is rapidly lost upon differentiation in cytokines supplemented liquid culture (after 3-5 days), even if recombinant Wnt3a or Wnt5a were added to culture (our unpublished data and Simon et al.
26
). The downregulation of b-catenin is phenotypically achieved in CD34 þ /low 38 þ 33 þ immature progenitors (data not shown), and is also specific to myelomonocytic differentiation. Indeed, under erythroid differentiation conditions, re-expression of high levels of b-catenin in proerythroblasts occurs without any maturation hiatus (our unpublished data). The finding of a loss of b-catenin expression, at a post-transcriptional level, despite Wnt stimulation in normal differentiating progenitors led us to check whether such an antagonistic regulating mechanism could be lost in AML. Wnts are ligands for a co-receptor made by Frizzled and LRP5/6, respectively specifically inhibited by FRP-1 and Dkk-1. Some Wnts are pro-(e.g. Wnt3a) and others anti-(e.g. Wnt5a) b-catenin through various couples of coreceptors. b-catenin in leukemic blasts and cell lines was readily stimulated by Wnt3a but not Wnt5a (Figure 3a , representative of 6/6 patients with low/undetectable b-catenin levels), or downregulated by recombinant frizzled related peptide-1 (FRP-1) (in two of three patients) or Dickkopf-1 (Dkk-1) (in one of two patients) (Figure 3b , and data not shown). We next used RT-PCR to check whether differences in b-catenin levels might be linked to the loss of the hematopoietic tumor suppressor Wnt5a (anti-bcatenin ligand) expression in blasts. 24 We noticed great variations in Wnt5a transcripts levels in six out of 11 consecutive subjects (Figure 3c) , that did not strictly correlate with b-catenin protein expression. Altogether, these results show that the Wnt/b-catenin pathway could be regulated in AML, as opposed to normal myelomonocytic differentiating precursors.
Discussion
We aimed to study b-catenin expression in a large cohort of patients to determinate whether it could influence blast behavior b-Catenin and clonogenic capacity in acute myeloid leukemia L Ysebaert et al in vivo. As already reported by previous publications, [25] [26] [27] we were able to find b-catenin in the majority of patients (nearly the two-thirds), although at very various levels. For analytical purposes, we chose a simple plus/minus stadification system, which appeared to us as the best way to avoid bias in the classification of patients, avoiding also the choice of a cell type with a reference level of b-catenin (a normal or malignant cell? At which maturation state?).
We established a correlation between b-catenin expression and clonogenic growth. Previous reports using clonogenic assays noted the inverse relationship between autonomous growth and the magnitude of response to growth factors, in that cells with low baseline proliferation kinetics are more readily stimulated. 28 This is also the case in our work, because b-catenin is correlated with proliferation under stimulation, not at baseline. Moreover, in our series, absence of prior myelodysplastic syndrome is correlated to autonomous growth (not shown), as previously demonstrated. 29 Leukemic cell growth in vitro has been correlated to poor OS in our study and in previous publications, and although b-catenin level and clonogenic properties (PE1 þ and PE2) are correlated, they are both independent prognostic factors for survival. It might be objected that b-catenin does not correlate with autonomous growth, which has been associated with poor prognosis in AML. [30] [31] It should be noticed that translocation products of t(8;21) and t (15;17) , that enhance Wnt signaling in leukemic cells, have not been linked to increased autonomous growth and that among AML, those with t(15;17) have been found to have enhanced PE1 þ rather than PE1À. 32 The major interest rather comes from the finding of a correlation between b-catenin expression and re-plating efficiency, which indicates a putative role of b-catenin in leukemic stem cells (LSCs). Moreover, since b-catenin was the only variable linked to relapse in our cohort, it could mean that a probably small pool of b-catenin-positive immature cells could drive the re-occurrence of the disease, although b-catenin was not correlated with chemoresistance in the bulk AML cells at diagnosis.
To understand how Wnt signaling could be deregulated in AML, we sought to determine b-catenin expression in normal hematopoiesis. We confirm that b-catenin expression is rapidly lost upon myelomonocytic differentiation. 26, 33 Interestingly, our preliminary results show that, depending on the way of maturation, erythroid for example, b-catenin could be reexpressed in CD34À cells (data not shown, and 33 ). We found that in M0-M2 AML patients (no M6 AML was tested), b-catenin expression was correlated with the median percentage of CD34 þ blasts, although this was not the case for M4-M5 AML. In unsorted bulk cells, b-catenin expression reflects the prevalence of CFU-L more accurately that CD34 expression (our data and 8, 26, 34 ). The loss of b-catenin in normal precursors coincides with the narrowing of their differentiating capacities (and the loss of CD34 antigen). Thus, the abnormal accumulation of b-catenin in leukemic cells (irrespective of their maturation and CD34 status) may confer clonogenic properties normally restricted to immature precursors.
To elucidate the mechanism(s) at stake in maintaining b-catenin in the majority of blasts, we further demonstrated a rapid modulation of b-catenin upon Wnt3a or FRP-1 ligation, indicating that AML blasts are fully responsive to both regulations of b-catenin levels, as opposed to differentiating normal myelomonocytic cells. These data imply that activation/ inactivation of b-catenin by the Wnt pathway is readily achievable in AML cells, 35 suggesting that (i) receptors are present, and (ii) downstream Wnt pathways are functional. In the hematopoietic tissue, Wnt5a is a tumor suppressor antagonizing Wnt signaling through b-catenin. 24 In our cohort, we could also find a differential expression of Wnt5a ligands in some patients (in a way indicating that Wnt signature could be shifted towards oncogenic Wnts at the expense of Wnt5a), but that does not strictly infirm other mechanism(s) to be responsible for b-catenin accumulation in other cases. Whether misexpression of Wnt receptors and/or secreted inhibitors of the pathway could be responsible for variations of b-catenin levels in patients remains to be elucidated. Our data pave the way to developing new therapeutic strategies aimed at inhibiting the Wnt pathway in clonogenic leukemic cells, like micro-environment manipulations (bone marrow stromal cells secrete Wnt ligands to support normal hematopoiesis 36 ), or Wnt-Tcf interactions for example (small molecules inhibitors have been developed 37 ).
